In Europe, CHMP missed an opportunity for osteoporosis patients at high risk of fracture

(International Osteoporosis Foundation) Experts from the International Osteoporosis Foundation and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases regret the recent decision by the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) to deny the marketing application for abaloparatide, a potential new treatment for postmenopausal women at high risk of fragility fracture which has been approved for use ...